A
ADCendo
Biotech & Life Sciences · Copenhagen, Denmark · Founded 2017
A Copenhagen-based biotech company dedicated to developing highly differentiated antibody-drug conjugates (ADCs) for the treatment of underserved cancers MoreLess
Adcendo is a biotechnology startup that specializes in the development of antibody-drug conjugates (ADCs), a type of cancer treatment that targets specific cancer cells. The company was founded in 2017 as a spin-off from the University of Copenhagen and Rigshospitalet. Its founders, Niels Behrendt, Lars Engelholm, and Christoffer Nielsen, have over 20 years of experience in cancer research and drug development.
Adcendo's primary focus is on the uPARAP receptor, a molecule involved in cancer development and metastasis. The founders have demonstrated that ADCs targeting this receptor can effectively treat cancer in preclinical models. This discovery led to the creation of Adcendo, which aims to further investigate and develop these findings into viable cancer treatments.
The company operates in the biotechnology and pharmaceutical market, serving clients such as hospitals, healthcare providers, and potentially, cancer patients. Its business model revolves around the research, development, and commercialization of its ADCs. Revenue is generated through the successful development and sale of these cancer treatments, as well as through partnerships with other biotech and pharmaceutical companies.
In 2021, Adcendo secured 51 million EUR in a series A investment round, which was extended by an additional 31 million EUR in 2023. This funding, provided by an international syndicate of life science and biotech investors, will support the company's ongoing research and development efforts.
Keywords: Biotechnology, Antibody-Drug Conjugates (ADCs), Cancer Treatment, uPARAP Receptor, Research and Development, University of Copenhagen, Rigshospitalet, Series A Funding, Biotech Investors, Pharmaceutical Market.
Company overview
ADCendo company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Copenhagen, Denmark
- Employees
- 63
- Open positions
- None listed
- Dealroom signal
- 67.5
Valuation & funding
ADCendo funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Apr 2026 | $70M | $712M | TPG · Bpifrance · Ysios Capital · Venrock | ↗ |
| SERIES BOther financing | Nov 2024 | $142M | $570M | Ysios Capital · HealthCap · Gilde Healthcare · OrbiMed | ↗ |
| SERIES AOther financing | May 2024 | $18M | $281M | Dawn Biopharma | ↗ |
| SERIES AOther financing | Apr 2023 | $34M | $281M | HealthCap · Gilde Healthcare · RA Capital Management · Ysios Capital | ↗ |
| SERIES AOther financing | Apr 2021 | $56M | $224M | Ysios Capital · HealthCap · Novo Seeds · Gilde Healthcare | — |
| DEBTDebt | Aug 2019 | Undisclosed | — | ||
| GRANTOther financing | Jan 2018 | Novo Nordisk Foundation | — | ||
| SPINOUTOther financing | Jan 2017 | University of Copenhagen · Rigshospitalet | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | EBITDA | Margin |
|---|---|---|
| 2026 | −$11M | — |
| 2025 | −$11M | — |
| 2024 | −$11M | — |
| 2023 | −$11M | — |
| 2022 | −$11M | — |
| 2021 | −$3.9M | — |
| 2020 | −$1.2M | — |
Growth signals
ADCendo website traffic
Latest recorded traffic for ADCendo is 3.6K monthly website visits, up 89.5% over the last three months. ADCendo's team declined 4.5% over the past year.
Hiring
Open positions at ADCendo
Current openings linked to this company in Dealroom.
Comparisons
ADCendo compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
ADCendo's talent
Source: Dealroom Talent Intelligence.
Investors
21 investors on ADCendo's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where ADCendo has talent and traffic
team presence
In the news
Latest news about ADCendo
Recent press, funding announcements, and product moves mentioning ADCendo — open to read from the original sources.
Market sentiment
What the market is saying about ADCendo
An AI-synthesized read of the highest-engagement posts about ADCendo on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ADCendo’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.